SOLODYN Drug Patent Profile

When do Solodyn patents expire, and what generic alternatives are available?

Solodyn is a drug marketed by Bausch and is included in one NDA. There are four patents protecting this drug and four Paragraph IV challenges.

This drug has twelve patent family members in nine countries.

The generic ingredient in SOLODYN is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Solodyn

A generic version of SOLODYN was approved as minocycline hydrochloride by WATSON LABS on December 30^th, 1991.

Summary for SOLODYN

International Patents:	12
US Patents:	4
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	19
Patent Applications:	2,725
Drug Prices:	Drug price information for SOLODYN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOLODYN
What excipients (inactive ingredients) are in SOLODYN?	SOLODYN excipients list
DailyMed Link:	SOLODYN at DailyMed

See drug prices for SOLODYN

See drug sales revenues for SOLODYN

Recent Clinical Trials for SOLODYN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Journey Medical Corporation	Phase 1
Dr. Reddy's Laboratories Limited	Phase 1
University of Washington	Phase 2

See all SOLODYN clinical trials

Paragraph IV (Patent) Challenges for SOLODYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SOLODYN	Extended-release Tablet	minocycline hydrochloride	105 mg	050808	1	2010-12-13
SOLODYN	Extended-release Tablet	minocycline hydrochloride	55 mg	050808	1	2010-12-02
SOLODYN	Extended-release Tablet	minocycline hydrochloride	80 mg	050808	1	2010-10-27
SOLODYN	Extended-release Tablet	minocycline hydrochloride	65 mg and 115 mg	050808	1	2009-11-19

US Patents and Regulatory Information for SOLODYN

SOLODYN is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-001	May 8, 2006		DISCN	Yes	No
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-002	May 8, 2006		DISCN	Yes	No
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-004	Jul 23, 2009		DISCN	Yes	No			Y
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-003	May 8, 2006		DISCN	Yes	No
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-002	May 8, 2006		DISCN	Yes	No			Y
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-008	Aug 27, 2010		DISCN	Yes	No

Expired US Patents for SOLODYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-002	May 8, 2006
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-006	Aug 27, 2010
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-008	Aug 27, 2010
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-003	May 8, 2006
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-006	Aug 27, 2010
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-001	May 8, 2006

International Patents for SOLODYN

See the table below for patents covering SOLODYN around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	564093	Method for the treatment of acne using an oral minocycline antibiotic
World Intellectual Property Organization (WIPO)	2010017310
China	101208097	Method for the treatment of acne
Canada	2613273	METHODE DE TRAITEMENT DE L'ACNE (METHOD FOR THE TREATMENT OF ACNE)
Australia	2006262428	Method for the treatment of acne
Japan	2008543936

SOLODYN (minocycline hydrochloride) market dynamics and financial trajectory

Last updated: April 25, 2026

What is SOLODYN and how has it competed in the branded acne antibiotic market?

SOLODYN is an extended-release (ER) formulation of minocycline hydrochloride for acne vulgaris, marketed in the U.S. by Scilbiopharma/Salix (brand history tied to Valeant/Salix). It competed in a defined niche: oral, ER tetracycline-class antibiotics for moderate to severe acne when long-duration suppression is used.

Key competitive attributes:

• Formulation advantage: Once-daily ER dosing, which reduces pill burden versus immediate-release regimens (mechanically important to adherence).
• Clinical positioning: Oral antibiotic option for inflammatory acne in established treatment algorithms.
• Regulatory pressure: Antibiotic stewardship constraints tightened across 2010s, raising friction for long-course prescribing of oral antibiotics for acne. This matters because SOLODYN’s value proposition depends on sustained use.

The market’s structural headwind is the same across oral acne antibiotics: stewardship guidance and payor controls reduce the duration and frequency of antibiotic use, even if clinical demand persists.

How do patent and exclusivity timelines shape SOLODYN’s revenue profile?

A branded acne antibiotic’s financial trajectory is dominated by exclusivity windows and generic entry. For SOLODYN, the economic arc is consistent with a branded-to-mature-to-generic transition typical of dermatology anti-infectives once formulation-specific protection and related exclusivity lapse.

Exclusivity and market impact (high-level timeline logic)

• Early lifecycle: Growth phase driven by differentiation (ER) and dermatologist adoption.
• Mid lifecycle: Revenue stabilizes as competitors and treatment guidelines cap long antibiotic courses.
• Late lifecycle: Generic minocycline ER and/or ANDA products pressure price and volumes.
• Post-entry: Brand pricing power compresses and revenue declines accelerate.

This pattern is visible across the class and is the central driver for the branded-to-generic step-down in dermatology antibiotics.

What do generic erosion dynamics imply for SOLODYN’s price, mix, and net sales?

Once generics enter, a branded ER product typically experiences:

• Unit volume loss as prescribers and pharmacies substitute.
• Net price compression due to wholesale/contracting shifts and PBM formulary preferences.
• Mix dilution as insured populations migrate to lower-cost alternatives.
• Residual demand that persists only where prescribers are locked into ER dosing preferences or where payor formularies maintain a preferred non-generic option.

For SOLODYN specifically, the mechanism is straightforward: generic substitution preserves the active ingredient (minocycline) and, where ER-equivalence is accepted, preserves the dosing convenience that differentiates the brand.

How did treatment guidelines and stewardship likely change demand?

Across the U.S. and EU, dermatology guidance evolved to limit oral antibiotic duration and emphasize topical agents, hormonal therapy, and isotretinoin where appropriate. The practical market effects on SOLODYN-type products are:

• Shorter antibiotic courses reduce cumulative use.
• Greater combination and topical reliance displaces monotherapy oral antibiotics.
• Higher barrier for new starts because payors and clinicians prefer “time-limited antibiotic + maintenance” strategies.

Even without a full prescription-claims dataset here, the financial trajectory for a branded oral acne antibiotic in this period is typically characterized by:

• Volatility from guideline adoption
• Sustained pressure on brand growth
• Accelerated decline post-generic entry

What does the branded-to-mature transition typically look like on the P&L?

For branded dermatology drugs facing generic erosion, financial trajectory usually shows:

• Gross margin compression from price cuts and mix deterioration.
• Promotional spend reduction as returns decline.
• Operating leverage loss if brand support remains costly but sales shrink.
• Net sales decline that outpaces cost reductions until the product is de-emphasized.

SOLODYN’s business case in late lifecycle therefore tends to shift from “growth investment” to “value capture,” and then to containment after generic penetration.

What are the key market dynamics investors should track for SOLODYN?

The following drivers determine whether the brand can retain residual revenue post-erosion:

1) Generic substitution speed

• Date of first ANDA launch and ramp
• Number of approved ANDAs
• Pharmacy stocking and PBM preference

2) Dosing-equivalence acceptance

• Bioequivalence performance for ER minocycline
• Clinical comfort with generic ER equivalence
• Interchange policies at PBM and pharmacy levels

3) Formulary and access

• Tier placement (preferred vs non-preferred)
• Prior authorization requirements for oral antibiotics
• Step edits that shift patients to topical or alternative oral options

4) Stewardship and prescribing norms

• Duration caps in guideline-aligned practice
• Increased use of non-antibiotic regimens

5) Safety and tolerability-driven switching

• Tetracycline-class adverse-event profile affects adherence and switching, impacting net volumes when multiple oral acne options coexist.

Financial trajectory: branded decline mechanics and likely inflection points

A branded ER minocycline product’s financial curve is typically segmented into three periods:

Period A: Launch and build

• Revenue scales with dermatologist uptake and ER adherence advantages.
• Net sales growth correlates with new starts and longer course adoption.

Period B: Guideline tightening

• Demand growth slows and net sales plateau or grow modestly.
• Prescribers shift toward limited-duration antibiotic strategies and non-antibiotic maintenance.

Period C: Generic entry and sustained erosion

• A sharp step-down occurs after generic launch.
• Revenue declines continue as share migrates and price resets.
• Brand may keep a smaller loyal base, but net sales trajectory trends downward.

How does SOLODYN compare with other branded oral acne therapies in market behavior?

SOLODYN’s dynamics should be read relative to other acne oral classes:

• Hormonal agents (where applicable): face different eligibility constraints and payer coverage patterns.
• Isotretinoin: severe acne gatekeeping and risk management make it less directly substitutable with antibiotics.
• Other oral antibiotics: compete on class economics; once generics exist, branded differentiation shrinks.

For oral antibiotics, the competitive equilibrium after generic entry is usually decided by access (formulary) and tolerability, not by brand identity.

Key takeaways

• SOLODYN’s demand is structurally tied to oral antibiotic acne prescribing, which has faced durable constraints from stewardship guidance.
• Generic erosion is the dominant driver of branded revenue decline: minocycline ER equivalence reduces the durable differentiation advantage.
• Financial trajectory should be expected to follow a classic three-phase pattern: build, guideline-driven normalization, then step-down and sustained erosion post-generic entry.
• The measurable predictors of residual brand value are generic substitution speed, dosing-equivalence acceptance, formulary access, and prescribing-duration norms.

FAQs

1) What is the main market risk for SOLODYN?

Generic substitution and guideline-driven limitations on long-course oral antibiotic use.

2) Does ER formulation meaningfully protect SOLODYN after generic launches?

It can delay erosion if prescribers strongly prefer ER dosing, but it does not prevent erosion once ER-generics gain formulary and substitution acceptance.

3) What should be monitored to anticipate revenue inflections?

ANDA launch timing, number of entrants, PBM formulary moves, and prior authorization or step-edit changes tied to oral antibiotic duration.

4) How do acne treatment guidelines affect oral antibiotic brands?

They reduce the expected duration and shift maintenance toward non-antibiotic regimens, lowering total prescriptions and cumulative use.

5) Where does residual brand demand typically come from?

Patients and prescribers who remain on the brand due to familiarity, tolerability experience, or payor constraints that temporarily slow substitution.

---

References

[1] U.S. Food and Drug Administration. Labeling and regulatory information for minocycline hydrochloride products (SOLODYN brand history and approval context). FDA. (Accessed via FDA Drugs@FDA).